7/23/2014 - 10:15 AM EST - Sirona Biochem Corp : announced that Wanbang Biopharmaceuticals has completed two pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and improved Oral Glucose Tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem. Sirona Biochem Corp
shares V.SBM are trading up $0.005 at $0.11.
